Download PDF
Thromb Haemost 2023; 123(01): 123-130
DOI: 10.1055/s-0042-1760263
Editors' Choice

Thrombosis and Haemostasis 2022 Editors' Choice Papers

Christian Weber
1   Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany
2   German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany
3   Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands
,
Xavier Blanchet
1   Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany
,
Gregory Y. H. Lip
4   Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
5   Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
› Author Affiliations
› Further Information
    Permissions and Reprints

The Editor's Choice from Thrombosis and Haemostasis as well as from its open access companion journal TH Open highlights the articles and reviews of the year that have achieved the greatest resonance among our readers. In 2022, the coronavirus disease 2019 (COVID-19) has remained an important topic mandating the need to interrogate the emergence and management of new viral infections.[1] Several of our most highly cited papers have dealt with bleeding and thrombotic complications, their diagnosis, and management in several pathologies, including cancer and pulmonary and COVID-19-associated cardiovascular diseases (CVDs).[2] [3] [4] [5] [6] Particular interest was also instigated by a new promising concept of the holistic or integrated care management approach of patients with stroke along with the definition of an “aortovascular hub” aligned with an integrated health care system.[7] [8]



Publication History

Article published online:
10 January 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Iba T, Levy JH, Levi M. Viral-induced inflammatory coagulation disorders: preparing for another epidemic. Thromb Haemost 2022; 122 (01) 8-19
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the 'Atrial Fibrillation Better Care' pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Chao T-F, Joung B, Takahashi Y. et al. 2021 Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Bikdeli B, Talasaz AH, Rashidi F. et al. Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial. Thromb Haemost 2022; 122 (01) 131-141
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Marcos-Jubilar M, Carmona-Torre F, Vidal R. et al; BEMICOP Investigators. Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP study): an open-label, multicenter, randomized, controlled trial. Thromb Haemost 2022; 122 (02) 295-299
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Agnelli G, Muñoz A, Franco L. et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost 2022; 122 (05) 796-807
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Field M, Kuduvalli M, Torella F, McKay V, Khalatbari A, Lip GYH. Integrated care systems and the aortovascular hub. Thromb Haemost 2022; 122 (02) 177-180
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Lip GYH, Ntaios G. “Novel Clinical Concepts in Thrombosis”: integrated care for stroke management-easy as ABC. Thromb Haemost 2022; 122 (03) 316-319
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Klug M, Lazareva O, Kirmes K. et al. Platelet surface protein expression and reactivity upon TRAP stimulation after BNT162b2 vaccination. Thromb Haemost 2022; 122 (10) 1706-1711
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Rodríguez-Pardo J, Gilo-Arrojo F, Ruiz-Ares G. et al. Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after covid-19 vaccine. Thromb Haemost 2022; 122 (02) 300-303
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Lindhoff-Last E, Schoenborn L, Piorkowski M. et al. Heterogeneity of vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination and safety of second vaccination with BNT162b2. Thromb Haemost 2022; 122 (02) 304-307
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors. Thromb Haemost 2021; 121 (11) 1395-1399
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Melkumyants A, Buryachkovskaya L, Lomakin N, Antonova O, Serebruany V. Mild COVID-19 and impaired blood cell-endothelial crosstalk: considering long-term use of antithrombotics?. Thromb Haemost 2022; 122 (01) 123-130
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Traby L, Kollars M, Kussmann M. et al. Extracellular vesicles and citrullinated histone H3 in coronavirus disease 2019 patients. Thromb Haemost 2022; 122 (01) 113-122
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Blasco A, Coronado M-J, Vela P. et al. Prognostic implications of neutrophil extracellular traps in coronary thrombi of patients with ST-elevation myocardial infarction. Thromb Haemost 2022; 122 (08) 1415-1428
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Gorog DA, Storey RF, Gurbel PA. et al. Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat Rev Cardiol 2022; 19 (07) 475-495
    CrossrefPubMedGoogle Scholar
  • 17 Mei F, Fan J, Yuan J. et al. Comparison of venous thromboembolism risks between COVID-19 pneumonia and community-acquired pneumonia patients. Arterioscler Thromb Vasc Biol 2020; 40 (09) 2332-2337
    CrossrefPubMedGoogle Scholar
  • 18 Cangemi R, Calvieri C, Falcone M. et al. Comparison of thrombotic events and mortality in patients with community-acquired pneumonia and COVID-19: a multicenter observational study. Thromb Haemost 2022; 122 (02) 257-266
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Fumagalli S, Trevisan C, Del Signore S. et al; GeroCovid Working Group. COVID-19 and atrial fibrillation in older patients: does oral anticoagulant therapy provide a survival benefit?-An insight from the GeroCovid registry. Thromb Haemost 2022; 122 (01) 105-112
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14 (11) 627-628
    CrossrefPubMedGoogle Scholar
  • 21 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2021 Editors' Choice Papers. Thromb Haemost 2022; 122 (01) 163-170
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian Paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost 2022; 122 (10) 1625-1652
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Kirchhof P, Camm AJ, Goette A. et al; EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020; 383 (14) 1305-1316
    Google Scholar
  • 25 Chao T-F, Chan Y-H, Chiang C-E. et al. Early rhythm control and the risks of ischemic stroke, heart failure, mortality, and adverse events when performed early (<3 months): a nationwide cohort study of newly diagnosed patients with atrial fibrillation. Thromb Haemost 2022; 122 (11) 1899-1910
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Kim D, Yang PS, You SC. et al. Comparative effectiveness of early rhythm control versus rate control for cardiovascular outcomes in patients with atrial fibrillation. J Am Heart Assoc 2021; 10 (24) e023055
    CrossrefPubMedGoogle Scholar
  • 27 Sun W, Freedman B, Martinez C, Wallenhorst C, Yan BP. Atrial fibrillation detected by single time-point handheld electrocardiogram screening and the risk of ischemic stroke. Thromb Haemost 2022; 122 (02) 286-294
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Wallenhorst C, Martinez C, Freedman B. Risk of ischemic stroke in asymptomatic atrial fibrillation incidentally detected in primary care compared with other clinical presentations. Thromb Haemost 2022; 122 (02) 277-285
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Kitsiou A, Rogalewski A, Kalyani M. et al. Atrial fibrillation in patients with embolic stroke of undetermined source during 3 years of prolonged monitoring with an implantable loop recorder. Thromb Haemost 2021; 121 (06) 826-833
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Kalarus Z, Mairesse GH, Sokal A. et al. Searching for atrial fibrillation: looking harder, looking longer, and in increasingly sophisticated ways. An EHRA position paper'. Europace 2022; (e-pub ahead of print) DOI: 10.1093/europace/euac144.
    CrossrefPubMedGoogle Scholar
  • 31 Proietti M, Boriani G. Screening for atrial fibrillation in relation to stroke and mortality risk. Thromb Haemost 2022; 122 (02) 171-175
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Jones NR, Crawford W, Yang Y, Hobbs FDR, Taylor CJ, Petrou S. A systematic review of economic aspects of service interventions to increase anticoagulation use in atrial fibrillation. Thromb Haemost 2022; 122 (03) 394-405
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Ivany E, Lotto RR, Lip GYH, Lane DA. Managing uncertainty: physicians' decision making for stroke prevention for patients with atrial fibrillation and intracerebral hemorrhage. Thromb Haemost 2022; 122 (09) 1603-1611
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Nelson AJ, Johnston BW, Waite AAC, Lemma G, Welters ID. A systematic review of anticoagulation strategies for patients with atrial fibrillation in critical care. Thromb Haemost 2021; 121 (12) 1599-1609
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Romiti GF, Proietti M, Bonini N. et al; GLORIA-AF Investigators. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III. Thromb Haemost 2022; 122 (12) 2030-2041
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Camelo-Castillo A, Rivera-Caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V. Predicting adverse events beyond stroke and bleeding with the ABC-stroke and ABC-bleeding scores in patients with atrial fibrillation: the Murcia AF project. Thromb Haemost 2020; 120 (08) 1200-1207
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 2017; 117 (01) 57-65
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Bonnesen K, Schmidt M, Horváth-Puhó E, Sørensen HT. The interaction effect between comorbidity burden and venous thromboembolism on mortality: a nationwide cohort study. Thromb Haemost 2022; 122 (04) 578-589
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 de Winter MA, Dorresteijn JAN, Ageno W. et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost 2022; 122 (05) 818-829
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Girard P, Laporte S, Chapelle C. et al. Failure of the Ottawa Score to predict the risk of recurrent venous thromboembolism in cancer patients: the prospective PREDICARE cohort study. Thromb Haemost 2022; 122 (01) 151-157
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Riedl JM, Schwarzenbacher E, Moik F. et al. Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing first-line chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Thromb Haemost 2022; 122 (04) 633-645
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Ow T-W, Fatourou E, Rabinowich L. et al. Prevalence of bleeding and thrombosis in critically ill patients with chronic liver disease. Thromb Haemost 2022; 122 (06) 1006-1016
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Cohen AT, Sah J, Dhamane AD. et al. Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease. Thromb Haemost 2022; 122 (06) 926-938
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Bertoletti L, Gusto G, Khachatryan A. et al. Effectiveness and safety of oral anticoagulants in the treatment of acute venous thromboembolism: a nationwide comparative cohort study in France. Thromb Haemost 2022; 122 (08) 1384-1396
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Mahé I, Agnelli G, Ay C. et al. Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT study. Thromb Haemost 2022; 122 (04) 646-656
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Meyer G, Vicaut E, Danays T. et al; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370 (15) 1402-1411
    CrossrefPubMedGoogle Scholar
  • 47 Sanchez O, Charles-Nelson A, Ageno W. et al; PEITHO-3 Investigators. Reduced-dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism: rationale and design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. Thromb Haemost 2022; 122 (05) 857-866
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Kim H-S, Kang J, Hwang D. et al; HOST-REDUCE-POLYTECH-ACS investigators. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet 2020; 396 (10257): 1079-1089
    CrossrefPubMedGoogle Scholar
  • 49 Lee HS, Park KW, Kang J, Han JK, Kim HS. De-escalation of prasugrel results in higher percentage of patients within optimal range of platelet reactivity: analysis from the HOST-REDUCE-POLYTECH-ACS trial. Thromb Haemost 2022; 122 (01) 160-162
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Davidson KW, Barry MJ, Mangione CM. et al; US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA 2022; 327 (16) 1577-1584
    CrossrefPubMedGoogle Scholar
  • 51 Calderone D, Greco A, Ingala S. et al. Efficacy and safety of aspirin for primary cardiovascular risk prevention in younger and older age: an updated systematic review and meta-analysis of 173,810 subjects from 21 randomized studies. Thromb Haemost 2022; 122 (03) 445-455
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Tullemans BME, Fernández DI, Veninga A. et al. Tyrosine kinase inhibitor sunitinib delays platelet-induced coagulation: additive effects of aspirin. Thromb Haemost 2022; 122 (01) 92-104
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost 2005; 3 (06) 1257-1265
    CrossrefPubMedGoogle Scholar
  • 54 Steirer LM, Park EI, Townsend RR, Baenziger JU. The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid α2,6-galactose. J Biol Chem 2009; 284 (06) 3777-3783
    CrossrefPubMedGoogle Scholar
  • 55 Lunghi B, Morfini M, Martinelli N. et al. The asialoglycoprotein receptor minor subunit gene contributes to pharmacokinetics of factor VIII concentrates in hemophilia A. Thromb Haemost 2022; 122 (05) 715-725
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Ichinose A, Osaki T, Souri M. Autoimmune coagulation factor X deficiency as a rare acquired hemorrhagic disorder: a literature review. Thromb Haemost 2022; 122 (03) 320-328
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Sharman Moser S, Chodick G, Ni YG. et al. The association between factor XI deficiency and the risk of bleeding, cardiovascular, and venous thromboembolic events. Thromb Haemost 2022; 122 (05) 808-817
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Preis M, Hirsch J, Kotler A. et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 2017; 129 (09) 1210-1215
    CrossrefPubMedGoogle Scholar
  • 59 Connolly SJ, Crowther M, Eikelboom JW. et al; ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380 (14) 1326-1335
    CrossrefPubMedGoogle Scholar
  • 60 Benz AP, Xu L, Eikelboom JW. et al; ANNEXA-4 Investigators. Andexanet alfa for specific anticoagulation reversal in patients with acute bleeding during treatment with edoxaban. Thromb Haemost 2022; 122 (06) 998-1005
    Article in Thieme ConnectPubMedGoogle Scholar
  • 61 Tsantes AG, Papadopoulos DV, Trikoupis IG. et al. The prognostic performance of rotational thromboelastometry for excessive bleeding and increased transfusion requirements in hip fracture surgeries. Thromb Haemost 2022; 122 (06) 895-904
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Margetić S, Ćelap I, Huzjan AL. et al. DOAC dipstick testing can reliably exclude the presence of clinically relevant DOAC concentrations in circulation. Thromb Haemost 2022; 122 (09) 1542-1548
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Navarese EP, Grisafi L, Spinoni EG. et al. Safety and efficacy of different antithrombotic strategies after transcatheter aortic valve implantation: a network meta-analysis. Thromb Haemost 2022; 122 (02) 216-225
    Article in Thieme ConnectPubMedGoogle Scholar
  • 64 Chappell J, Harman JL, Narasimhan VM. et al. Extensive proliferation of a subset of differentiated, yet plastic, medial vascular smooth muscle cells contributes to neointimal formation in mouse injury and atherosclerosis models. Circ Res 2016; 119 (12) 1313-1323
    CrossrefPubMedGoogle Scholar
  • 65 Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J Am Coll Cardiol 2010; 55 (15) 1553-1565
    CrossrefPubMedGoogle Scholar
  • 66 Mause SF, Ritzel E, Deck A, Vogt F, Liehn EA. Endothelial progenitor cells modulate the phenotype of smooth muscle cells and increase their neointimal accumulation following vascular injury. Thromb Haemost 2022; 122 (03) 456-469
    Article in Thieme ConnectPubMedGoogle Scholar
  • 67 Field ML, Kuduvalli M, Torella F, Lip GY. Aortovascular medicine: what is it?. J R Soc Med 2021; 114 (10) 467-469
    CrossrefPubMedGoogle Scholar
  • 68 Kamel H, Okin PM, Elkind MSV, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke 2016; 47 (03) 895-900
    CrossrefPubMedGoogle Scholar
  • 69 Lip GYH, Lane DA, Lenarczyk R. et al. Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. Eur Heart J 2022; 43 (26) 2442-2460
    CrossrefPubMedGoogle Scholar
  • 70 Guo Y. A new paradigm of “real-time” stroke risk prediction and integrated care management in the digital health era: innovations using machine learning and artificial intelligence approaches. Thromb Haemost 2022; 122 (01) 5-7
    Article in Thieme ConnectPubMedGoogle Scholar
  • 71 Lip GYH, Genaidy A, Tran G, Marroquin P, Estes C, Sloop S. Improving stroke risk prediction in the general population: a comparative assessment of common clinical rules, a new multimorbid index, and machine-learning-based algorithms. Thromb Haemost 2022; 122 (01) 142-150
    Article in Thieme ConnectPubMedGoogle Scholar
  • 72 Veninga A, Baaten CCFMJ, De Simone I. et al. Effects of platelet agonists and priming on the formation of platelet populations. Thromb Haemost 2022; 122 (05) 726-738
    Article in Thieme ConnectPubMedGoogle Scholar
  • 73 King SL, Joshi HJ, Schjoldager KT. et al. Characterizing the O-glycosylation landscape of human plasma, platelets, and endothelial cells. Blood Adv 2017; 1 (07) 429-442
    CrossrefPubMedGoogle Scholar
  • 74 Li R, Hoffmeister KM, Falet H. Glycans and the platelet life cycle. Platelets 2016; 27 (06) 505-511
    CrossrefPubMedGoogle Scholar
  • 75 Zieger B, Boeckelmann D, Anani W. et al. Novel GNE gene variants associated with severe congenital thrombocytopenia and platelet sialylation defect. Thromb Haemost 2022; 122 (07) 1139-1146
    Article in Thieme ConnectPubMedGoogle Scholar
  • 76 Pennings GJ, Reddel CJ, Traini M. et al. Rapid release of interleukin-1β from human platelets is independent of NLRP3 and caspase. Thromb Haemost 2022; 122 (04) 517-528
    Article in Thieme ConnectPubMedGoogle Scholar
  • 77 Santovito D, Weber C. Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease. Nat Rev Cardiol 2022; 19 (09) 620-638
    CrossrefPubMedGoogle Scholar
  • 78 Pedersen OB, Grove EL, Kristensen SD, Nissen PH, Hvas AM. MicroRNA as biomarkers for platelet function and maturity in patients with cardiovascular disease. Thromb Haemost 2022; 122 (02) 181-195
    Article in Thieme ConnectPubMedGoogle Scholar